Brief: Tela Bio Announces U.S. Commercial Launch Of Two New Ovitex® Lpr Device Configurations To Repair Large Abdominal Hernias Using Robotic And Laparoscopic Techniques
21/02/2023 12:15
Feb 21 (Reuters) - TELA Bio Inc TELA.O :
* TELA BIO ANNOUNCES U.S. COMMERCIAL LAUNCH OF TWO NEW
OVITEX® LPR
DEVICE CONFIGURATIONS TO REPAIR LARGE ABDOMINAL HERNIAS USING
ROBOTIC AND LAPAROSCOPIC TECHNIQUES
Source text for Eikon: ID:nGNX1Y23kd
Further company coverage: TELA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TELA Bio
See all newsBrief: Tela Bio - Receives FDA 510(K) Clearance For Liora Monofilament Scaffold For Soft Tissue Reinforcement
Tela Bio Inc Reports Results For The Quarter Ended June 30: Earnings Summary
TELA Bio Q2 revenue falls on lower OviTex PRS volumes, withdraws outlook
Brief: TELA Bio Q2 Revenue USD 19.291 Million Vs. IBES Estimate USD 20 Million
Tela Bio Inc Expected To Post A Loss Of 18 Cents A Share: Earnings Preview